Income statement
USD
Annual
| Metric | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|
| Revenue | 0 | 54K | 114K | 73K | 344K |
| Gross Profit | 0 | 17K | 64K | 47K | 252K |
| Operating Income | -1M | -2M | -2M | 4M | -2M |
| EBITDA | -1M | -2M | -2M | -4M | -2M |
| Net Income | -2M | -2M | -2M | -19M | -2M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.0001
+0.00% today
1Y Change
+0.00%
Window
Jun 23, 2025 → Jun 9, 2026
Coverage: 242 bars · Jun 23, 2025 → Jun 9, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Pathfinder Cell Therapy, Inc. (PFND) is a Healthcare stock with listed on OTC. The stock last traded around $0.00 and up 0.0% across the available one-year price window (Jun 23, 2025 → Jun 9, 2026). Baseline metrics include revenue growth of -100.0%, EPS growth of +7.4%, a dividend yield of 0.0%. What stands out right now is revenue -100.0%, EPS +7.4%, free cash flow +39.9% with operating margin 0.0% and ROIC 116.6%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines PFND price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PFND
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
PFND Max Drawdown
0.00%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for PFND and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$344.0K
+371.2% YoY
FY Net Income
-$2.1M
+89.0% YoY
Free Cash Flow
-$1.3M
+44.6% YoY
Revenue Growth
-100.0%
EPS Growth
+7.4%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|
| Revenue | 0 | 54K | 114K | 73K | 344K |
| Gross Profit | 0 | 17K | 64K | 47K | 252K |
| Operating Income | -1M | -2M | -2M | 4M | -2M |
| EBITDA | -1M | -2M | -2M | -4M | -2M |
| Net Income | -2M | -2M | -2M | -19M | -2M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|
| Cash & Equivalents | 26K | 44K | 9K | 196K | 10K |
| Total Assets | 106K | 155K | 356K | 644K | 145K |
| Total Liabilities | 6M | 5M | 3M | 1M | 1M |
| Shareholder Equity | -6M | -5M | -3M | -707K | -973K |
| Total Debt | 5M | 4M | 2M | 318K | 462K |
| Net Debt | 5M | 4M | 2M | 122K | 452K |
Cash flow positioning
Latest Full Year
Operating Cash Flow
1M
+44.6% YoY
Capital Expenditures
0
Free Cash Flow
1M
+44.6% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
31.8%
Debt / Equity
-0.84x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.